Lars Hahn, Senior Vice President, Global Sales Organization, Vetter Pharma International GmbH, a CDMO of drug product development, clinical, and commercial aseptic filling and packaging, outlined major expansions to increase the company’s manufacturing footprint in Europe and the United States, amounting to a total long-term global investment strategy of approximately EUR 2 billion ($2.33 billion). He outlined the plan at the DCAT Member Company Announcement Forum, held March 23, 2025, at DCAT Week.  

Vetter announced earlier this year (January 2026) its plans to build a new commercial production facility in the southwestern German state of Saarland. The company has acquired a 95-acre industrial property that will be developed in phases using a modular approach. Construction of the first phase is scheduled to begin in the second quarter of 2026, with an initial investment of approximately EUR 480 million ($560 million).The new plant will focus on Phase III and commercial parenteral drug manufacturing, supported by infrastructure such as laboratories, storage facilities, and technical services. Vetter expects to create up to 1,500 jobs during the final stage of the initial construction phase. The site is expected to be operational by 2031. The company is headquartered in Ravensburg, Germany, with additional manufacturing, packaging, and logistics sites around Ravensburg as well as a production facility in Langenargen, Germany. 

Complementing its European growth, Vetter is advancing the construction of a new clinical manufacturing facility in Des Plaines, Illinois. Following the groundbreaking ceremony in June 2025, work is continuing on the 18-acre property, which will house a 160,000-square-foot aseptic fill–finish facility dedicated to early-phase clinical development. With planned investments of approximately EUR 250 million ($292 million), the project is set to reach several major construction milestones in 2026, including the completion of the structural steelwork and the building’s dry-in. Site readiness is expected by the end of 2029. With this new facility, Vetter is strengthening its presence in the US market and supplementing its existing clinical network in Skokie, Illinois, and Rankweil, Austria.